Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919329 | 0.85 | HMGCR (0.30) | — | |
| SCHEMBL14107808 | 0.79 | CTSL (0.37) | GABRA5PDE4D | |
| SCHEMBL4893196 | 0.79 | CTSL (0.37) | GABRA5PDE4D | |
| SCHEMBL6575559 | 0.77 | PDE4D (0.39) | PDE4D | |
| SCHEMBL7493619 | 0.76 | PDE4D (0.34) | GABRA5PDE4D | |
| SCHEMBL4899890 | 0.76 | PDE4D (0.34) | GABRA5PDE4D | |
| SCHEMBL4895151 | 0.73 | CTSL (0.36) | GABRA5 | |
| SCHEMBL14107809 | 0.73 | CTSL (0.36) | GABRA5 | |
| SCHEMBL21029509 | 0.72 | CTSL (0.41) | — | |
| SCHEMBL22906947 | 0.72 | CTSL (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1210347-B1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA V Z W (BE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | GABRA5 2996/4885PDE4D 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.